Private company

KalVista Pharmaceuticals, Inc.

American pharmaceutical preparations company based in Cambridge.

Last updated Oct 18, 2026.

Overview

-$183.4MNet income, fiscal 2025²

IndustryPharmaceutical Preparations
HeadquartersCambridge, United States
Incorporated inDE³
Business address200 Crossing Boulevard, Framingham, Ma 01702³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-280.9%Operating margin²

-253.3%Net margin²

-61.3%Return on equity²

-$89.3MFree cash flow²

Where the money goes

Where each dollar of revenue went, fiscal 2024

Research and development

Research and development100¢$86.2M

Out of $50.0M in revenue.⁴² The company lost money this year.

Financial statements

Revenue⁵⁶⁷⁴$50.0M in 2024+496% since 2018

Operating income⁵⁶⁷⁸⁹²-$140.4M in 2024+651% since 2018

Net income⁵⁶⁷⁸⁹²-$126.6M in 2024+701% since 2018

Fiscal year	2018	2019	2020	2021	2022	2023	2024
Revenue	$8.4M⁵	$16.1M⁶	$12.7M⁷				$50.0M⁴
Research and development	$18.2M⁵	$35.0M⁶	$40.2M⁷	$41.3M⁸	$70.2M⁹	$80.3M⁹	$86.2M²
Operating income	-$18.7M⁵	-$29.8M⁶	-$40.5M⁷	-$57.9M⁸	-$96.6M⁹	-$110.9M⁹	-$140.4M²
Interest
Income tax	$0¹²	$124.0K⁶	-$124.0K⁷	$0⁸	$0⁹	$0⁹	$0²
Net income	-$15.8M⁵	-$20.8M⁶	-$29.1M⁷	-$46.2M⁸	-$82.3M⁹	-$92.9M⁹	-$126.6M²
Earnings per share			-$1.64⁷	-$2.42⁸	-$3.36⁹	-$3.33⁹	-$3.44²
Earnings per share (diluted)			-$1.64⁷	-$2.42⁸	-$3.36⁹	-$3.33⁹	-$3.44²

Total assets¹³⁵⁶⁷⁸⁹²$235.4M in 2024+283% since 2018

Shareholders’ equity⁶⁷⁸⁹²$206.6M in 2024+658% since 2018

Cash¹³⁵⁶⁷⁸⁹²$31.8M in 2024−38% since 2018

Fiscal year	2018	2019	2020	2021	2022	2023	2024
Cash	$51.1M¹³	$32.0M⁵	$15.8M⁶	$50.6M⁷	$30.7M⁸	$56.2M⁹	$31.8M²
Current assets	$59.4M¹³	$115.5M⁵	$88.7M⁶	$264.3M⁷	$193.6M⁸	$172.3M⁹	$225.7M²
Total assets	$61.4M¹³	$118.1M⁵	$92.5M⁶	$272.0M⁷	$203.9M⁸	$183.2M⁹	$235.4M²
Current liabilities	$23.2M¹³	$18.1M⁵	$7.7M⁶	$9.8M⁷	$11.6M⁸	$15.0M⁹	$22.8M²
Total liabilities
Shareholders’ equity	$27.3M⁶	$96.7M⁷	$83.8M⁸	$257.2M⁹	$185.1M⁹	$161.0M²	$206.6M²
Shares outstanding	10.8M shares¹²	17.4M shares¹³	17.8M shares⁵	24.4M shares⁶	24.6M shares⁷	34.2M shares⁸	42.7M shares⁹

Cash from operations⁵⁶⁷⁸⁹²-$89.2M in 2024

Capital spending⁵⁶⁷⁸⁹²$42.0K in 2024−97% since 2018

Free cash flow⁵⁶⁷⁸⁹²-$89.3M in 2024

Fiscal year	2018	2019	2020	2021	2022	2023	2024
Cash from operations	$10.6M⁵	-$36.4M⁶	-$44.8M⁷	-$30.2M⁸	-$78.1M⁹	-$75.3M⁹	-$89.2M²
Capital spending	$1.4M⁵	$1.1M⁶	$220.0K⁷	$82.0K⁸	$931.0K⁹	$1.2M⁹	$42.0K²
Free cash flow	$9.1M	-$37.4M	-$45.0M	-$30.3M	-$79.1M	-$76.5M	-$89.3M

Compare KalVista Pharmaceuticals, Inc. with another company

Leadership

Who has led KalVista Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

20202025

Chief executive officerBenjamin L. Palleiko Mar 8, 2024 to now¹⁴
Chief executive officerThomas Andrew Crockett Nov 28, 2016 to Feb 21, 2024¹⁵
Chief executive officerDavid Renzi Aug 5, 2015 to Nov 23, 2016¹⁶
PresidentBenjamin L. Palleiko Feb 23, 2023 to Nov 21, 2023¹⁷
PresidentThomas Andrew Crockett Nov 28, 2016 to Nov 28, 2016¹⁵
PresidentDavid Renzi Aug 5, 2015 to Nov 23, 2016¹⁶
Chief financial officerBrian Piekos Sep 11, 2024 to now¹⁸
Chief financial officerBenjamin L. Palleiko Nov 28, 2016 to Feb 21, 2024¹⁹

Board members and other officers (35)

Chief Commercial OfficerNicole Sweeny Aug 25, 2025 to now²⁰
Chief Operations OfficerBilal Arif Oct 8, 2025 to now²¹
Chief Medical OfficerPaul K. Audhya May 4, 2021 to now²²
Senior Vice President MedicalAndreas Maetzel Mar 9, 2017 to May 28, 2021²³
Chief Development OfficerChristopher Yea Nov 29, 2016 to now²⁴
Chief Scientific OfficerEdward P. Feener Nov 30, 2016 to May 21, 2024²⁵
OfficerDavid M. Gravett Apr 8, 2015 to Jan 5, 2016²⁶
OfficerDavid Renzi Apr 8, 2015 to Apr 8, 2015²⁷
OfficerHayley Lewis Apr 8, 2015 to Aug 5, 2015²⁸
OfficerMarcee Maroney Apr 8, 2015 to Nov 22, 2016²⁹
Vice President of Supply ChainPremchandran Ramiya Aug 5, 2015 to Jan 5, 2016³⁰
OfficerJohn McKune Aug 12, 2015 to Jan 5, 2016³¹
Board memberBethany Sensenig Oct 2, 2025 to now³²
Board memberBenjamin L. Palleiko Mar 8, 2024 to now¹⁴
Board memberWilliam Fairey Apr 22, 2024 to now³³
Board memberLaurence Reid Nov 26, 2024 to now³⁴
Board memberPatrick Treanor May 27, 2022 to now³⁵
Board memberNancy Stuart Mar 19, 2021 to now³⁶
Board memberBrian Jg Pereira Feb 5, 2019 to now³⁷
Board memberDaniel B. Soland Apr 23, 2019 to Oct 1, 2021³⁸
Board memberMartin Edwards Jun 28, 2019 to Oct 4, 2021³⁹
Board memberPeter Kolchinsky Oct 16, 2017 to Oct 16, 2017⁴⁰
Board memberRajeev M. Shah Nov 23, 2016 to Oct 16, 2017⁴¹
Board memberArnold L. Oronsky Nov 28, 2016 to Oct 2, 2020⁴²
Board memberThomas Andrew Crockett Nov 28, 2016 to Feb 21, 2024¹⁵
Board memberJoshua Resnick Nov 29, 2016 to Sep 29, 2017⁴³
Board memberRichard Aldrich Nov 29, 2016 to Oct 5, 2018⁴⁴
Board memberAlbert Cha Apr 8, 2015 to Sep 28, 2023⁴⁵
Board memberDavid M. Clapper Apr 8, 2015 to Aug 5, 2015⁴⁶
Board memberDavid Renzi Apr 8, 2015 to Nov 23, 2016²⁷
Board memberEdward W. Unkart Apr 8, 2015 to now⁴⁷
Board memberGuy P. Nohra Apr 8, 2015 to Apr 14, 2015⁴⁸
Board memberKeith Katkin Apr 8, 2015 to Aug 5, 2015⁴⁹
Board memberReza Zadno Apr 8, 2015 to Aug 5, 2015⁵⁰
Board memberSteven L. Basta Apr 8, 2015 to Nov 22, 2016⁵¹

Former names

Carbylan Therapeutics, Inc.Sep 19, 2014 to Nov 21, 2016³
Carbylan Biosurgery, IncJan 3, 2013 to Jan 3, 2013³
Carbylan Biosurgery IncDec 29, 2005 to Dec 29, 2005³

Timeline

Mar 8, 2024New chief executive Benjamin L. Palleiko becomes CEO¹⁴
Nov 28, 2016New chief executive Thomas Andrew Crockett becomes CEO¹⁵
Aug 5, 2015New chief executive David Renzi becomes CEO¹⁶

Filings

430 filings to the SEC since October 2021: 6 annual reports, 14 quarterly reports, 49 major events, 229 insider forms, 70 large holders, 62 other. The latest 20:

Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 11, 2026SCHEDULE 13G EDGAR
Jun 22, 202615-12G EDGAR
Jun 16, 2026EFFECT EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 202625-NSE EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR

The 430 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 70 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARKalVista Pharmaceuticals, Inc. filings on SEC EDGAR
2
SEC EDGARKalVista Pharmaceuticals, Inc. 10-K for fiscal 2025
3
SEC EDGARKalVista Pharmaceuticals, Inc. filings on SEC EDGAR
4
SEC EDGARKalVista Pharmaceuticals, Inc. 10-K for fiscal 2024
5
SEC EDGARKalVista Pharmaceuticals, Inc. 10-K for fiscal 2018
6
SEC EDGARKalVista Pharmaceuticals, Inc. 10-K for fiscal 2019
7
SEC EDGARKalVista Pharmaceuticals, Inc. 10-K for fiscal 2020
8
SEC EDGARKalVista Pharmaceuticals, Inc. 10-K for fiscal 2021
9
SEC EDGARKalVista Pharmaceuticals, Inc. 10-K for fiscal 2022
10
SEC EDGARKalVista Pharmaceuticals, Inc. 10-Q for fiscal 2025
11
SEC EDGARKalVista Pharmaceuticals, Inc. 10-Q for fiscal 2026
12
SEC EDGARKalVista Pharmaceuticals, Inc. 10-K for fiscal 2018
13
SEC EDGARKalVista Pharmaceuticals, Inc. 10-K for fiscal 2018
14
SEC EDGARBenjamin L. Palleiko, Chief executive officer
15
SEC EDGARThomas Andrew Crockett, Chief executive officer
16
SEC EDGARDavid Renzi, Chief executive officer
17
SEC EDGARBenjamin L. Palleiko, President
18
SEC EDGARBrian Piekos, Chief financial officer
19
SEC EDGARBenjamin L. Palleiko, Chief financial officer
20
SEC EDGARNicole Sweeny, Chief Commercial Officer
21
SEC EDGARBilal Arif, Chief Operations Officer
22
SEC EDGARPaul K. Audhya, Chief Medical Officer
23
SEC EDGARAndreas Maetzel, Senior Vice President Medical
24
SEC EDGARChristopher Yea, Chief Development Officer
25
SEC EDGAREdward P. Feener, Chief Scientific Officer
26
SEC EDGARDavid M. Gravett, Officer
27
SEC EDGARDavid Renzi, Officer
28
SEC EDGARHayley Lewis, Officer
29
SEC EDGARMarcee Maroney, Officer
30
SEC EDGARPremchandran Ramiya, Vice President of Supply Chain
31
SEC EDGARJohn McKune, Officer
32
SEC EDGARBethany Sensenig, Board member
33
SEC EDGARWilliam Fairey, Board member
34
SEC EDGARLaurence Reid, Board member
35
SEC EDGARPatrick Treanor, Board member
36
SEC EDGARNancy Stuart, Board member
37
SEC EDGARBrian Jg Pereira, Board member
38
SEC EDGARDaniel B. Soland, Board member
39
SEC EDGARMartin Edwards, Board member
40
SEC EDGARPeter Kolchinsky, Board member
41
SEC EDGARRajeev M. Shah, Board member
42
SEC EDGARArnold L. Oronsky, Board member
43
SEC EDGARJoshua Resnick, Board member
44
SEC EDGARRichard Aldrich, Board member
45
SEC EDGARAlbert Cha, Board member
46
SEC EDGARDavid M. Clapper, Board member
47
SEC EDGAREdward W. Unkart, Board member
48
SEC EDGARGuy P. Nohra, Board member
49
SEC EDGARKeith Katkin, Board member
50
SEC EDGARReza Zadno, Board member
51
SEC EDGARSteven L. Basta, Board member